DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

ProductUpdated on 22 April 2026

Entry portal through the intestinal barrier

Sven ARNOUTS

Technology Transfer & Innovation Leader at Ghent University - provaxs

Merelbeke, Belgium

About

Controlled transfer of biological compounds through the intestinal (mucosal) barrier via targeting of the compound to a defined receptor (APN) on the epithelium.

Via selective transcytosis through the intestinal barrier various functions at the level of the intestinal epithelium and beyond can be modulated: i) antigens can be efficiently presented to the gut associated lymphoid tissue (GALT) leading to a protective mucosal immune response and ii) drugs or drug-containing (nano-)particles can be transferred and delivered across the intestinal barrier.

Proof of concept for oral vaccination in the pig

Oral immunization of pigs with rabbit anti-APN antibodies leads to higher antibody responses when compared to immunization with a control rabbit antibody.

Partnering

We seek partners for licensing specific applications of our targeting technology and investors for a new start-up on the targeting technology platform.

Looking for

  • Commercial Partner
  • Strategic Partner
  • Industry Partner
  • Technology Partner
  • Licensing Partner
  • Investor
  • Manufacturing Partner

Applies to

  • Animal Health Biotechnology
  • Veterinary Vaccines
  • Livestock Farming
  • Antimicrobial Resistance Solutions

Organisation

Ghent University - provaxs

Merelbeke, Belgium

Similar opportunities